Chronic Lymphocytic Leukemia | Specialty

Dr. Lunning on Trials Evaluating BTK Inhibitors in CLL

August 3rd 2022

Matthew A. Lunning, DO, FACP, discusses trials evaluating BTK inhibitors in chronic lymphocytic leukemia.

Fixed-Duration Venetoclax/Obinutuzumab Provides Robust PFS Benefit in Untreated CLL

July 29th 2022

Othman Al-Sawaf, MD, discusses the 5-year follow-up data of the phase 3 CLL14 trial and emphasized the importance of fixed-duration treatments in high-risk patients with chronic lymphocytic leukemia.

Ibrutinib Plus Obinutuzumab Elicits Intriguing Survival Benefits in Relapsed/Refractory CLL

July 27th 2022

Christine Ryan, MD, discussed the evaluation of safety and efficacy of ibrutinib plus obinutuzumab in patients with relapsed/refractory CLL in the trial and how the results could result in another treatment option for patients with relapsed/refractory CLL.

Dr. Ryan on the Investigation of Ibrutinib Plus Obinutuzumab in Relapsed/Refractory CLL

July 26th 2022

Christine Ryan, MD, discusses the investigation of ibrutinib plus obinutuzumab in relapsed/refractory chronic lymphocytic leukemia.

Zanubrutinib Displays Improved Efficacy Vs Orelabrutinib in Relapsed/Refractory CLL/SLL and MCL

July 22nd 2022

Zanubrutinib demonstrated a significant improvement in progression-free survival compared with orelabrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma or mantle cell lymphoma.

Zanubrutinib Showcases Superior PFS Benefit Over BR in Treatment-Naïve CLL/SLL, Including High-Risk Subsets

July 20th 2022

Zanubrutinib was found to significantly improve progression-free survival over a doublet comprised of bendamustine plus rituximab in patients with treatment-naïve chronic lymphocytic leukemia and small lymphocytic lymphoma, according to data from cohort 1 of the phase 3 SEQUOIA trial.

Pirtobrutinib Demonstrates Encouraging Efficacy, Favorable Safety in Previously Treated CLL/SLL

July 14th 2022

Pirtobrutinib continued to produce promising responses in heavily pretreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, irrespective of BTK C481 mutation status, reason for prior BTK inhibitor discontinuation, or other classes of previous therapy received.

Ibrutinib/Obinutuzumab Combo Elicits Durable Responses in Relapsed/Refractory CLL

July 13th 2022

Findings from a phase 1b trial showed that the addition of obinutuzumab to ibrutinib produced a complete response rate that compared favorably with what has historically been observed with ibrutinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia.

FDA Issues Warning for Increased Risk of Death, Serious AEs with Duvelisib in CLL/SLL

July 1st 2022

The FDA has warned that treatment with duvelisib has shown a possible increased risk of death and serious adverse effects compared with ofatumumab in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

Emerging Therapies for Adults with R/R B-ALL

June 28th 2022

Considerations and Next Steps For Patients Who Progress on CAR T-Cell Therapy

June 28th 2022

Practical considerations for treatment selection in patients who progress on CAR T-Cell therapy.

Tisagenlecleucel as a Potential Option for Adult Patients with R/R B-ALL

June 28th 2022

Dr. Jae Park comments on the findings from the ELIANA study and tisagenlecleucel as a potential option for adults with R/R B-ALL.

Highlights from the Two-Year Follow-Up Results of the ZUMA-3 Trial

June 28th 2022

An oncologist specializing in the treatment of patients with B-ALL discusses the study design, efficacy, safety, and two-year updated results of the phase I/II ZUMA-3 study evaluating brexucabtagene autoleucel in adult patients with R/R B-ALL.

A Review of Available Treatment Options for Adult Patients with R/R B-ALL

June 28th 2022

Jae Park, MD, shares an overview of available therapeutic options for patients with R/R B-ALL.

Nemtabrutinib Generates Responses, Displays Manageable Safety in CLL/SLL

June 20th 2022

Nemtabrutinib, a potent, non-covalent BTK inhibitor, continued to demonstrate antitumor activity with an acceptable safety profile in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Ibrutinib Plus Venetoclax Produces High MRD Negativity Rate in Previously Untreated CLL

June 15th 2022

The addition of venetoclax to ibrutinib resulted in a high rate of minimal residual disease negativity in the blood and marrow of patients with previously untreated chronic lymphocytic leukemia.

Zanubrutinib Improves QOL Outcomes Vs Bendamustine/Rituximab in CLL/SLL

June 13th 2022

Zanubrutinib achieved favorable health-related quality of life outcomes compared with bendamustine plus rituximab in patients with treatment-naïve chronic lymphocytic leukemia and small lymphocytic lymphoma.

Venetoclax Plus Obinutuzumab Confers Long-Term Survival Benefits in Unfit Patients With CLL

June 13th 2022

Venetoclax plus obinutuzumab remains an effective fixed-duration treatment option for patients with chronic lymphocytic leukemia and coexisting conditions, according to updated efficacy and safety data from the ongoing phase 3 CLL14 trial.

BRUIN CLL-313 Trial To Evaluate Pirtobrutinib in Untreated CLL/SLL

June 12th 2022

The phase 3 BRUIN CLL-313 trial is currently recruiting patients with treatment naïve chronic lymphocytic leukemia or small lymphocytic lymphoma to evaluate the efficacy and safety of pirtobrutinib monotherapy vs bendamustine plus rituximab.

Dr. Sharman on 5-Year Data From the Elevate CLL TN Trial in CLL

June 11th 2022

Jeff Sharman, MD, discusses 5-year follow-up data from the phase 3 Elevate CLL TN trial in treatment-naïve patients with chronic lymphocytic leukemia.